Product/Composition:- | Pioglitazone And Metformin Tablets |
---|---|
Strength:- | Pioglitazone 15/30 mg + Metformin 500/850/1000 mg |
Form:- | Tablets |
Reference Brands:- | Actoplus Met (USA), Competact (EU) |
MOQ | As per the manufacturer batch size |
Get Quote Send Enquiry on WhatsApp |
Pioglitazone enhances insulin sensitivity in muscle and adipose tissue by activating PPAR-γ receptors, while Metformin reduces hepatic glucose production and improves peripheral glucose uptake. This synergistic combination effectively lowers blood glucose levels in type 2 diabetes, enhances glycemic control, and may support weight neutrality with improved insulin responsiveness.
Pioglitazone + Metformin tablets are approved in the EU and selectively in the USA as combination therapy for type 2 diabetes mellitus when diet, exercise, and monotherapy are insufficient. In the EU, these are regulated under the EMA and marketed under various brand names, while in the US, FDA approval varies by formulation. The combination offers dual benefits: Pioglitazone improves insulin sensitivity, while Metformin decreases hepatic glucose production. Regulatory agencies emphasize cardiovascular risk assessment and liver monitoring. Pharmatradz.com connects global B2B pharmaceutical buyers and sellers for Pioglitazone + Metformin tablets across regulated and semi-regulated markets efficiently and reliably.